$BMRN · BIOMARIN PHARMACEUTICAL INC
BioMarin filed an 8-K disclosing the estimated financial impact of its Alesta Therapeutics acquisition, completed August 31, 2026. The company expects ~$283M in acquired IPR&D expense for Q3 2026 and ~$320M in total pre-tax charges for FY2026. These translate to an unfavorable EPS impact of ~$1.50 for Q3 and ~$1.55 for the full year on both a GAAP and Non-GAAP basis. The charges were not reflected in the company's August 6, 2026 guidance.
- Alesta Therapeutics acquisition closed August 31, 2026, triggering ~$283M in acquired IPR&D expense for Q3 2026.
- Total FY2026 pre-tax charges from the Alesta deal expected to reach ~$320M, including transaction and transition costs.
- Q3 2026 GAAP and Non-GAAP Diluted EPS each face an unfavorable impact of ~$1.50 from the acquisition.
- Full-year 2026 GAAP and Non-GAAP Diluted EPS each face an unfavorable impact of ~$1.55.
- Prior FY2026 guidance issued August 6, 2026 did not reflect the Alesta acquisition; updated guidance coming with Q3 results.
Markets closed — no regular-session reaction yet; extended-hours move not captured here. The $320M charge and ~$1.55 EPS headwind represent a material deviation from prior guidance that was issued without the Alesta deal factored in.
A $320M unguided charge that hits both GAAP and Non-GAAP EPS by ~$1.55 materially resets FY2026 expectations for a $10.87B biotech — investors will reprice ahead of Q3 earnings.
Large acquired IPR&D charges are common in biopharma M&A but the $320M total hit — undisclosed in August guidance — is substantial relative to BioMarin's $10.87B market cap and will reset FY2026 earnings expectations.
Q3 2026 results are preliminary and not yet finalized; actual charges could differ from the $283M Q3 and $320M FY estimates. BioMarin does not provide reconciliations for forward-looking Non-GAAP measures, limiting comparability.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.